@article{7ea156d5ce7f4cb1a3ff9105d7f31fa2,
title = "Allergic and hypersensitivity conditions in non-specialist care: flow-diagrams to support clinical practice ",
abstract = "Most patients presenting with allergies are first seen by primary care health professionals. The perceived knowledge gaps and educational needs were recently assessed in response to which the LOGOGRAM Task Force was established with the remit of constructing pragmatic flow-diagrams for common allergic conditions in line with an earlier EAACI proposal to develop simplified pathways for the diagnosis and management of allergic diseases in primary care. To address the lack of accessible and pragmatic guidance, we designed flow-diagrams for five major clinical allergy conditions: asthma, anaphylaxis, food allergy, drug allergy and urticaria. Existing established allergy guidelines were collected and iteratively distilled to produce five pragmatic and accessible tools to aid diagnosis and management of these common allergic problems. Ultimately, they should now be validated prospectively in primary care settings.",
author = "Dermot Ryan and {Flokstra-de Blok}, B. and Evangeline Clark and Clara Gaudin and Myriam Mamodaly and Janwillem Kocks and {van der Velde}, Tina and Liz Angier and Kerstin Romberg and Radek Gawlik and Pascal Demoly and Tanno, {Luciana Kase}",
note = "Funding Information: The TF was sponsored by EAACI. Funding Information: DR: Has received remuneration for educational initiatives or speaker fees from: Chiesi, Viatris, GSK, AZ, Trudell, Regeneron, Novartis. PD: Has received remuneration for board and/or speaker bureau from Chiesi, IQVIA, M{\'e}narini, Sanofi, Regeneron, AstraZeneca, Bausch & Lomb, ThermoFisher Scientific, Mylan, Novartis. KR: received remuneration for educational initiatives or speaker fees from: Astra Zeneca, ALK, Boehrinrer Ingelheim, Chiesi, GSK, Mylan, Mundipharma and Novartis. JK: reports grants, personal fees and non‐financial support from AstraZeneca, grants, personal fees and non‐financial support from Boehringer Ingelheim, grants and personal fees from Chiesi, grants, personal fees and non‐financial support from GSK, non‐financial support from Mundi Pharma, grants and personal fees from Teva, personal fees from MSD, personal fees from COVIS Pharma, grants from Valneva outside the submitted work; and Janwillem Kocks holds <5% shares of Lothar Medtec GmbH and 72.5% of shares in the General Practitioners Research Institute. BFB: was employed by General Practitioners Research Institute (GPRI) at the time of the study. In the past 3 years (2019–2021), GPRI conducted investigator‐ and sponsor‐initiated research funded by non‐commercial organizations, academic institutes, and pharmaceutical companies (including AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, and Teva). All other authors declare no COI. Publisher Copyright: {\textcopyright} 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.",
year = "2022",
month = mar,
day = "10",
doi = "10.1111/all.15273",
language = "English",
journal = "Allergy",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
}